Imagine a heart attack as a burn that leaves a permanent scar, making the heart stiff and weak. This technology acts like a smart, temporary scaffold that supports the heart wall and blocks scar tissue from forming. Once the heart heals, the material simply dissolves safely into the body.
Current treatments for heart attacks fail to prevent scar tissue and cardiac remodelling, leaving millions of patients at risk of heart failure.
A recombinant elastin-like hydrogel and a matching minimally invasive endocardial catheter, supported by GMP manufacturing protocols.
If you are a device manufacturer dealing with the limitations of current post-MI interventions — this project developed a minimally invasive endocardial catheter that delivers a specialized hydrogel to prevent irreversible cardiac remodelling.
If you are a biotech firm dealing with the difficulty of scaling lab-grade hydrogels — this project developed GMP manufacturing SOPs and a fed-batch synthesis method for elastin-like recombinant hydrogels.
If you are a healthcare provider dealing with the high cost of treating 26.5 million IHD patients in Europe — this project developed a therapeutic intervention to reduce heart failure risk and long-term patient burden.
Based on available project data, specific pricing is not provided, but the project is developing a health economic evaluation to assess potential savings and patient benefits.
Yes, the project is currently refining production using a fed-batch hydrogel synthesis method and has documented Standard Operating Procedures (SOPs) for GMP manufacturing.
The project is actively developing intellectual property rights (IPR) strategies in preparation for first-in-human validation studies.
The consortium is developing regulatory strategies to move the hydrogel and catheter toward a first-in-human (FIH) validation study.
The project runs until 2026-11-30, aiming to reach the preparedness level for a first-in-human study by the end of the period.
The consortium is highly commercially oriented, with a 50% industry ratio consisting of 4 industrial partners, including 3 SMEs. This balance between 3 universities and 1 research institute suggests a strong push toward translation, specifically focusing on GMP manufacturing and catheter delivery systems.
Contact the University of Galway for details on the ELR-SCAR preclinical validation results.
Contact us to explore licensing opportunities for the ELR-hydrogel GMP processes.
